Uso Terapéutico de los Cannabinoides en la Enfermedad De Parkinson. Revisión

  1. Tamara Rivero López 1
  2. Luis G. Hernández-Abad 2
  3. Ignacio de la Cruz Muros
  4. Ibrahim González Marrero 1
  1. 1 Departamento de Ciencias Médicas Básicas Universidad de La Laguna
  2. 2 Instituto de Investigación y Ciencias de Puerto del Rosario
Revue:
Majorensis: Revista Electrónica de Ciencia y Tecnología

ISSN: 1697-5529

Année de publication: 2019

Número: 15

Pages: 1-8

Type: Article

DIALNET GOOGLE SCHOLAR lock_openAccès ouvert editor

D'autres publications dans: Majorensis: Revista Electrónica de Ciencia y Tecnología

Résumé

La enfermedad de Parkinson es una enfermedad neurodegenerativa, compleja y crónica. Con ella se produce un deterioro progresivo del sistema nervioso central, en los pacientes que la padecen.Aunque en la actualidad no existe cura, existen muchísimas formas terapéuticas para combatir la sintomatología de la enfermedad en cada una de sus fases y así mejorar la calidad de vida del paciente. Con esta revisión bibliográfica se pretende conocer a través de los estudios realizados, la opción del uso de cannabinoides como posible tratamiento en enfermedades neurodegenerativas, centrándonos en la enfermedad de Parkinson.

Références bibliographiques

  • Aguado T, Monory K, Palazuelos J, Stella N, Cravatt B, Lutz B, Marsicano G, Kokaia Z, Guzmán M, Galve-Roperh I. The endocannabinoid system drives neural progenitor proliferation. FASEB J. 2005;19(12):1704-6. Epub 2005 Jul 21.
  • Benard, G., F. Massa, N. Puente, J. Lourenco, L. Bellocchio, E. Soria-Gomez, I. Matias, A. Delamarre, M. MetnaLaurent, A. Cannich, E. Hebert-Chatelain, C. Mulle, S. Ortega-Gutierrez, M. MartinFontecha, M. Klugmann, S. Guggenhuber, B. Lutz, J. Gertsch, F. Chaouloff, M. L. Lopez-Rodriguez, P. Grandes, R. Rossignol , G. Marsicano. Mitochondrial CB(1) receptors regulate neuronal energy metabolism. Nat Neurosci 2012;15(4): 558-564.
  • Broussolle E, Thobois S. [Genetic and environmental factors of Parkinson's disease]. Rev Neurol (Paris) 2002; 158: 11-23.
  • Carroll CB, Bain PG, Teare L, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology. 2004;63:1245–1250.
  • Chagas MH, Eckeli AL, Zuardi AW, et al. Cannabidiol can improve complex sleeprelated behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series. J Clin Pharm Ther. 2014;39:564–566.
  • Chagas MH, Zuardi AW, Tumas V, et al. Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory doubleblind trial. J Psychopharmacol. 2014;28:1088–1098.
  • De Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006; 5: 525-35.
  • Di Marzo V, Melck D, Bisogno T, De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 1998;21:521–8
  • Finseth TA, Hedeman JL, Brown RP 2nd, et al. Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson’s disease patients in Colorado. Evid Based Complement Alternat Med 2015;2015:874849.
  • Forno LS. Neurophatology of Parkinson´s disease. J Neuropathol Exp Neurol 1996; 55:259-272.
  • Fraguas A, Fernández A, Torres A. Cannabinoides: una prometedora herramienta para el desarrollo de nuevas terapias. Real Academia Nacional de Farmacia 2014; 80:555-577.
  • Frankel JP, Hughes A, Lees AJ, et al. Marijuana for parkinsonian tremor. J Neurol Neurosurg Psychiatry. 1990;53:436.
  • Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995 15;232(1):54-61.
  • Gerard, C. M., C. Mollereau, G. Vassart, M. Parmentier. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 1991;279(Pt 1):129-134.
  • Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 2015;172:4790–805.
  • Lotan I, Treves TA, Roditi Y, et al. Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. Clin Neuropharmacol 2014;37:41–44.
  • Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol 2005;(168):299-325.
  • Molina-Holgado F, Molina-Holgado E, Guaza C, Rothwell NJ. Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharideinduced nitric oxide release in astrocyte cultures. J Neurosci Res 2002 15;67(6):829-36.
  • Parkinson J. An Essay on the Shaking Palsy. London: Neely, and Jones, 1817.
  • Prasad KN, Cole WC, Kumar B. Multiple antioxidants in the prevention and treatment of Parkinson's disease. J Am Coll Nutr 1999; 18: 413-23.
  • Sánchez C, Galve-Roperh I, Rueda D, Guzmán M. Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the Delta9- tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. Mol Pharmacol 1998;54(5):834-43.
  • Szabo, B., E. Schlicker. Effects of cannabinoids on neurotransmission. Handb Exp Pharmacol 2005;168: 327-365.
  • Velasco L, Ruiz L, Sánchez MG, DíazLaviada I. delta(9)-Tetrahydrocannabinol increases nerve growth factor production by prostate PC-3 cells. Involvement of CB1 cannabinoid receptor and Raf-1. Eur J Biochem 2001;268(3):531-5.
  • Venderova´ K, Ruzicka E, Vorı´sek V, et al. Survey on cannabis use in Parkinson’s disease: subjective improvement of motor symptoms. Mov Disord. 2004;19:1102– 1106.
La source de données: Dialnet